Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Métodos Terapêuticos e Terapias MTCI
Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Pediatr Blood Cancer ; 69(10): e29888, 2022 10.
Artigo em Inglês | MEDLINE | ID: mdl-35856619

RESUMO

This is the first study examining real-life data of pediatric cancer patients treated with rivaroxaban. Children with thrombocytopenia and high bleeding risk were excluded from previous clinical trials. Data regarding the safety and efficacy of rivaroxaban in pediatric cancer-associated thrombosis are scarce. Our case series included 16 children aged 7.5-17 years. Thrombus resolution rate in our study was comparable to results of previous studies. However, higher rates of thrombotic and bleeding complications were seen in our study as compared to previous reports, especially among patients with relapsed or refractory disease.


Assuntos
Neoplasias , Trombose , Tromboembolia Venosa , Anticoagulantes/uso terapêutico , Criança , Inibidores do Fator Xa/efeitos adversos , Hemorragia/induzido quimicamente , Hemorragia/complicações , Humanos , Neoplasias/complicações , Neoplasias/tratamento farmacológico , Rivaroxabana/efeitos adversos , Trombose/tratamento farmacológico , Resultado do Tratamento , Tromboembolia Venosa/etiologia
2.
Platelets ; 23(8): 604-10, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22273510

RESUMO

Glanzmann's thrombasthenia (GT) is characterized by increased bleeding risk. The treatment options in GT are limited. The aim of this study was to test the effect of GT blood supplementation with fibrinogen and factor XIII on thrombin generation, blood clotting, and fibrinolysis. Whole blood samples of GT patients and normal donors treated with eptifibatide (GT model) were subjected to clotting by CaCl(2) and tissue factor. Thrombin generation was measured in platelet-rich plasma. Clot formation and tPA-induced fibrinolysis were evaluated in whole blood by rotation thromboelastometry (ROTEM). Blood was supplemented with fibrinogen (3 g/L) and/or FXIII (2 IU/mL). Thrombin generation analysis of blood derived from GT model and GT patients revealed decreased endogenous thrombin potential and peak height and extended lag time compared to control. However, this method was not sensitive to blood spiking with fibrinogen and FXIII. ROTEM revealed lower maximum clot firmness (MCF) and area under curve (AUC) in the blood of GT model and GT patients. In the absence of exogenous tPA, blood spiking with fibrinogen markedly enhanced clot quality while FXIII had no effect. Combination of fibrinogen and FXIII did not add to the effect of fibrinogen. In contrast, by the addition of tPA, both fibrinogen and FXIII separately and, to more extent, in combination enhanced clot quality as well as resistance against tPA-induced fibrinolysis (increasing MCF, AUC, and lysis onset time). In conclusion, fibrinogen and FXIII exerted stimulation of blood clotting and inhibition of fibrinolysis. Treating normal blood with eptifibatide mimics the changes of coagulopathy in GT blood.


Assuntos
Coagulação Sanguínea/efeitos dos fármacos , Fator XIII/farmacologia , Fibrinogênio/farmacologia , Trombastenia/sangue , Trombina/metabolismo , Área Sob a Curva , Cloreto de Cálcio/farmacologia , Estudos de Casos e Controles , Eptifibatida , Humanos , Peptídeos/farmacologia , Inibidores da Agregação Plaquetária/farmacologia , Plasma Rico em Plaquetas/química , Tromboelastografia , Trombina/agonistas , Tempo de Trombina , Tromboplastina/farmacologia , Ativador de Plasminogênio Tecidual/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA